More on Abaxis (ABAX): Q1 beats on a per share basis but misses on revenue, despite a 17% Y/Y...
More on Abaxis (ABAX): Q1 beats on a per share basis but misses on revenue, despite a 17% Y/Y rise in total sales. Revenues from instruments +31%, consumables +12%, medical market sales -18%, medical sales worldwide, excluding sales to the U.S. government, -20%. Shares -5.8% AH.
From other sites
at CNBC.com (Sep 22, 2014)
at CNBC.com (Nov 15, 2013)
at CNBC.com (Jul 16, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs